Osel Devices
- Market cap
- ₹ 605 Cr.
- P/E
- 20.7x
- P/B
- 2.88x
- 52-week range
- 320 – 835
- ROE
- 20%
- ROCE
- 24%
- Dividend yield
- 0%
- Debt / equity
- 0.47
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- NSE SME
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 25 companies →Osel Devices against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)20.7 against a typical 26.9: cheaper than most peers (1st = cheapest).7th of 25
- Sales growth+78% against a typical +21.5% from a year earlier.4th of 18
- Profit growth+75% against a typical +13.4% from a year earlier.3rd of 16
- Share price, 3 months−18.7% against a typical −6.4%.18th of 23
- Size₹ 605 Cr. market value against a typical ₹ 238.1 Cr. (1st = largest).9th of 24
Latest announcements
Exchange filings and their impact on the company.
- Clarifies preferential warrants to non-promoter for working capital with 6-month lock-in and Rs 362 valuation.
Osel Devices clarified its planned preferential issue of convertible warrants to a non-promoter investor. The sole purpose is additional working capital, with a 6-month lock-in on conversion shares. An independent valuer pegged fair value at Rs 362 per share versus around Rs 340 market price. The funds, once approved and converted, should help fund growth and reduce reliance on short-term debt.
- Board declares Rs 1 interim dividend and approves 1.7 lakh warrants at Rs 412 to public investors.
Osel Devices board on October 17, 2026 declared a first interim dividend of Rs 1 per Rs 10 share for FY27 with record date October 24, 2026, with Managing Director Rajendra Ravi Shanker Mishra waiving dividend on his 1.15 crore shares. It also approved issuing up to 1,70,000 convertible warrants at Rs 412 per share to non-promoter public investors, subject to shareholder approval at an EGM on November 12, 2026, raising about Rs 7 crore. The board also appointed Kapil Kohli as Strategic Consultant for distribution and growth.
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Moderate safety, with caution
Rated BBB by CRISIL- No warnings from the agency.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| CRISIL | Crisil BBB | Positive | 5 Feb 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 5 Feb 2026 | Reaffirmed | Crisil BBB | — | CRISIL | ₹ 48 Cr. | |
| 28 Nov 2025 | Rating action | Crisil BBB | — | CRISIL | ₹ 45 Cr. |
Fund raises
QIPs, preferential issues, warrants and rights issues, one row per filing, newest first. Open a row for details. All fund raise updates
| Stage | Details | |||||
|---|---|---|---|---|---|---|
| 27 Oct 2026 | Warrants | Shareholders approved | — | — | — | |
| 17 Oct 2026 | Warrants | Board approved | ₹ 7 Cr. | ₹ 412 | −17.33% |
Research by Minerva Capital Research Solutions
Our research team's work on Osel DevicesAlso covered in
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 17 Oct 2026 | Dividend/Fund Raising | To consider dividend and Fund Raising |
| 29 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 12 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 30 Jul 2025 | Fund Raising | To consider Fund Raising |
| 26 May 2025 | Financial Results | To consider and approve the financial results for the period ended March 31, 2025 |
| 15 May 2025 | Fund Raising | To consider Fund Raising |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Sales | 51 | 82 | 87 | 99 | 147 | 146 |
| Expenses | 42 | 68 | 74 | 79 | 122 | 117 |
| Operating Profit | 9 | 14 | 13 | 20 | 25 | 29 |
| OPM % | 17% | 17% | 15% | 20% | 17% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 2 |
| Interest | 1 | 2 | 2 | 2 | 4 | 6 |
| Depreciation | 0 | 0 | 0 | 1 | 1 | 1 |
| Profit before tax | 7 | 12 | 11 | 18 | 20 | 24 |
| Tax % | 26% | 35% | 29% | 32% | 26% | 41% |
| Net Profit | 5 | 8 | 8 | 12 | 15 | 14 |
| EPS in Rs | 26.6 | 6.7 | 4.97 | 7.46 | 8.58 | 7.95 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- 39%
- 3 Years
- 53%
- TTM
- 57%
- 10 Years
- —
- 5 Years
- 85%
- 3 Years
- 84%
- TTM
- 46%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- —
- TTM
- —
- 10 Years
- —
- 5 Years
- 27%
- 3 Years
- 26%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Prices are delayed and for information only. Nothing on this page is investment advice.